fluticasone furoate + umeclidinium bromide + vilanterol trifenatate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate: clinical details
Prescribing considerations
- Confirm the COPD indication and inadequate control on an appropriate dual combination.
- Not indicated for acute bronchospasm or an acute COPD exacerbation; increasing reliever use warrants reassessment.
- Review inhaler technique, adherence and ability to generate an effective dry-powder inhalation.
- Use caution with unstable or life-threatening cardiovascular disease, moderate to severe hepatic impairment, pulmonary tuberculosis, chronic or untreated infection, thyrotoxicosis or convulsive disorders.
- Assess risks from pneumonia, narrow-angle glaucoma, urinary retention and systemic corticosteroid exposure.
Contraindications and cautions
- Hypersensitivity to any active ingredient or excipient.
- Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
- The selected product should not be used for asthma.
Monitoring
- COPD symptoms, exacerbations and quick-acting reliever use
- Inhaler technique and adherence
- Signs of pneumonia, which may overlap with COPD exacerbation
- Plasma glucose more closely after initiation in people with diabetes
- Visual symptoms, urinary retention and clinically significant cardiovascular effects
- Systemic corticosteroid adverse effects in moderate to severe hepatic impairment
Clinical pharmacology
An inhaled ICS/LAMA/LABA combination. Fluticasone furoate suppresses airway inflammation; umeclidinium competitively inhibits muscarinic receptors, particularly M3-mediated bronchoconstriction; vilanterol activates beta₂ receptors to relax airway smooth muscle.
Formulation and product differences
- A pre-dispensed, lactose-containing dry powder in the Ellipta device.
- After opening the sealed tray, record the discard date and protect the inhaler from moisture; the desiccant must not be swallowed or inhaled.
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate preparations and strengths
Inhaled preparation
Route: Inhaled
Strengths: 92 micrograms + 55 micrograms + 22 micrograms
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate interactions
Ask a prescriber or pharmacist to review other medicines and inhalers, particularly:
Beta-blockers, including propranolol
May oppose vilanterol's bronchodilator effect; concurrent use requires caution.
Strong CYP3A4 inhibitors, including ketoconazole, ritonavir or cobicistat
Can increase exposure to fluticasone and vilanterol and raise the risk of systemic adverse effects.
Other long-acting muscarinic antagonists or long-acting beta₂ agonists
Concurrent use is not recommended because overlapping effects and adverse reactions may be amplified.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.